Buy Nimbex ampoules 2 mg/ml, 5 ml, 5 pcs
  • Buy Nimbex ampoules 2 mg/ml, 5 ml, 5 pcs

Nimbex® [Cisatracurium besylate]

GlaxoSmithKline
Dosage form
Brand & Manufacturer
Package Size
$89.06
Quantity
There are not enough products in stock
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

NIMBEX - non-depolarizing muscle relaxant of average duration of action, causes a blockade of neuromuscular transmission. This effect can be quickly eliminated by anticholinesterase drugs. Not able to cause the release of histamine and does not affect the cardiovascular system. Metabolites do not have muscle relaxant activity.

Indications

Myorelaxation during surgery, tracheal intubation, mechanical ventilation.

Composition

Cisatracurium besylate.

No customer reviews for the moment.

Write your review

Write your review

Nimbex® [Cisatracurium besylate]

Dosage and Administration

Intravenous, bolus. In adults and children from 1 month. up to 12 years for tracheal intubation - 0.15 mg / kg, quickly, within 5-10 s. In 2-3 minutes after the injection, a neuromuscular block occurs, sufficient for tracheal intubation. With the introduction of higher doses, the block occurs faster. Sequential administration of maintenance doses does not lead to a progressive increase in the duration of the effect. After the spontaneous recovery of the neuromuscular block has begun, its rate does not depend on the total dose administered.

Adverse reactions

The adverse reactions presented below are listed in accordance with the damage to organs and organ systems and the frequency of occurrence. The frequency of occurrence is defined as follows: very often (≥1 / 10); often (≥1 / 100 and <1/10); infrequently (≥1 / 1000 and <1/100), rarely (≥1 / 10000 and <1/1000), very rarely (<1/10000, including isolated cases). Frequency categories were formed on the basis of clinical studies of the drug and post-marketing observation. Clinical trial data From the side of the heart: often - bradycardia. From the side of the vessels: often - a decrease in blood pressure; infrequently - skin redness. From the respiratory system, chest and mediastinal organs: infrequently - bronchospasm. Skin and subcutaneous tissue disorders: infrequently - rash. Post-registration observation data From the immune system: very rarely - anaphylactic reactions. Anaphylactic reactions can vary in severity and severity after administration of muscle relaxants. Very rarely, the occurrence of severe anaphylactic reactions has been reported in patients who received Nimbex in combination with one or more anesthetics. Musculoskeletal and connective tissue disorders: very rarely - myopathy, muscle weakness. There have been several cases of myopathy and / or muscle weakness associated with prolonged use of muscle relaxants in critically ill patients in the intensive care unit, most of whom received concomitant corticosteroid therapy. A causal relationship with the administration of cisatracurium besylate in these rare cases has not been established.
  • Brand name: Nimbex
  • Active ingredient: Cisatracurium besylate
  • Dosage form: Injection
  • Manufacturer: GlaxoSmithKline
  • Country of Origin: Great Britain

Studies and clinical trials of Cisatracurium besylate (Click to expand)

  1. HPLC determination of cisatracurium besylate and propofol mixtures with LC-MS identification of degradation products
  2. Anticancer effects of vecuronium bromide and cisatracurium besylate on lung cancer cells (A549), in vitro
  3. Influence of acute normovolaemic haemodilution on the dose-response relationship and time course of action of cisatracurium besylate
  4. The effect of different storage temperature on the pharmacodynamic dose-response of cisatracurium besylate
  5. Dose–Response Relationship and Infusion Requirement of Cisatracurium Besylate in Infants and Children during Nitrous Oxide–Narcotic Anesthesia
  6. Dose-Response Relationship and Infusion Requirement of Cisatracurium Besylate in Infants and Children During Nitrous Oxide-Narcotic Anesthesia
  7. Capillary electrophoresis with electrochemiluminescence detection for the simultaneous determination of cisatracurium besylate and its degradation products in pharmaceutical preparations
  8. Preclinical pharmacology of cisatracurium besylate
  9. Pharmacokinetics and Pharmacodynamics of a 0.1 mg/kg Dose of Cisatracurium Besylate in Children During N2O/O2/Propofol Anesthesia
  10. Influence of Acute Normovolaemic Hemodilution on the Dose-Response Relationship and Time Course of Action of Cisatracurium Besylate
  11. Autophagic Cell Death and Apoptosis Jointly Mediate Cisatracurium Besylate-Induced Cell Injury
  12. Stability of cisatracurium besylate in vials, syringes, and infusion admixtures
  13. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration

8 other products in the same category:

arrow_upward